{"id":"NCT03298867","sponsor":"Amgen","briefTitle":"Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study","officialTitle":"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-04","primaryCompletion":"2019-02-13","completion":"2020-11-30","firstPosted":"2017-10-02","resultsPosted":"2020-03-10","lastUpdate":"2024-07-11"},"enrollment":83,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Thyroid Eye Disease","Graves' Orbitopathy"],"interventions":[{"type":"BIOLOGICAL","name":"Teprotumumab","otherNames":["HZN-001"]},{"type":"OTHER","name":"Placebo","otherNames":["Saline solution"]}],"arms":[{"label":"Teprotumumab 20 mg/kg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody \\[mAb\\] inhibitor of the insulin-like growth factor-1 receptor \\[IGF-1R\\]) administered once every 3 weeks (q3W) for 21 weeks with a final assessment at Week 24, in comparison to placebo, in the treatment of participants with moderate-to-severe active thyroid eye disease (TED).","primaryOutcome":{"measure":"Percentage of Participants Who Were Proptosis Responders at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo","deltaMin":9.5,"sd":null},{"arm":"Teprotumumab 20 mg/kg","deltaMin":82.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States","Germany","Italy"]},"refs":{"pmids":["31971679","33172865"],"seeAlso":["https://www.tepezza.com/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":42},"commonTop":["Muscle Spasms","Alopecia","Diarrhoea","Nausea","Headache"]}}